High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease

I. Maleki, A. Rastgar, V. Hosseini, T. Taghvaei, A. Rafiei, M. Barzin, Z. Torabizadeh, F. Naghshvar, A. Khalilian

Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, School of Medicine, Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Molecular and Cell Biology Research Center, Department of Radiology, Department of Pathology, Department of Statistics; Mazandaran University of Medical Sciences, Sari, Iran. zhtorabi@yahoo.com

---

• Gastroenterology

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) has become the most common hepatic disease. Liver biopsy is the gold standard for the diagnosis of NAFLD. To overcome the problems with liver biopsy many studies are being performed to find noninvasive methods for the evaluation of hepatic status.

AIM: This study aims to study to role of high sensitive CRP and pentraxine 3 in the setting of NAFLD

PATIENTS AND METHODS: thirty two NAFLD cases and 34 controls were enrolled. All subjects were studied clinically and blood was drawn for para-clinical studies. Liver biopsy was performed for all cases. Levels of hs-CRP and pentraxine were analyzed to find any significant difference for the stages of steatosis and fibrosis based on pathologic findings.

RESULTS: Hs-CRP level was higher in nonalcoholic steatohepatitis (NASH) cases versus non-NASH cases. Its level was also increased in higher levels of fibrosis. Pentraxine 3 had no efficacy in differentiating different levels of NAFLD and fibrosis.

CONCLUSIONS: Hs-CRP can be used in combination with other biomarkers in the noninvasive evaluation of NAFLD.

Free PDF Download